Preclinical Drug Development: Focus on ADME, PK/PD Modelling

Aim

Drug-receptor interaction, impact of DMPK on drug development, relevance of transporters, mechanisms for DMPK interactions, reactive metabolites, toxikokinetics, interspecies scaling, drug-likeness, in vitro testing for DMPK properties, ADME screening, in silico prediction of DMPK properties, alternatives for animal experimentsPre-clinical and clinical extrapolation of PK/PD, drug-action and response, Biomarkers, Surrogates and Clinical endpoints, Principles of population PK/PD modelling and clinical trials simulation, application in the design and evaluation of phase III clinical trials

Location & Organization

Organizer

ECPM - European Center of Pharmaceutical Medicine, University of Basel

Faculty / Teachers

Theodor W. Guentert, F. Hoffmann-La Roche AG, Basel; Nick Holford, University of Auckland, Auckland, Meindert Danhof, University of Leiden, NL; Don Stanski, Novartis AG; Basel; Jean-Louis Steimer, Novartis, Basel; Ronald Gieschke, F. Hoffmann-La Roche AG, Basel; C. Funk, F. Hoffmann-La Roche AG, Basel; M. Kansky, F. Hoffmann-La Roche AG, Basel; Mike Doherty, F. Hoffmann-La Roche AG, Basel; Thomas Singer, F. Hoffmann-La Roche AG, Basel; Lucette Doessegger, F. Hoffmann-La Roche AG, Basel; Friedlieb Pfannkuch, F. Hoffmann-La Roche AG, Basel

Location / venue

University of Basel

Timing & Workload

Duration Four days
ECTS points 2
 

Teaching methods used

Teaching course incl. case studies

Examination yes

Criteria

Is the course taught in English? yes
Is documentation available? (book, syllabus)? yes
Is the course open for external researchers? yes

Remarks

Compulsory module in ECPM master program Drug Development Sciences

More Information

http://www.ecpm.ch